This difference in potency may explain the numerically higher ORRs and longer PFS with divarasib compared to sotorasib and adagrasib, as a single-agent and in combination with an EGFR inhibitor in patients with CRC. This evidence concerns the gene EGFR and colorectal carcinoma.